NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT04666805 2020-12-14
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
First Hospital of China Medical University
Unknown
NCT02344940 2019-09-24
TTOS
Shanghai Jiao Tong University School of Medicine
Phase 4 Completed
NCT02506790 2019-09-04
Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Unknown
NCT03238703 2018-12-27
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Fred Hutchinson Cancer Center
Phase 4 Withdrawn
NCT03351062 2017-11-22
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Chinese Anti-Cancer Association
Phase 3 Unknown
NCT02097459 2016-05-25
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT02132390 2014-06-04
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
Peking Union Medical College Hospital
Phase 3 Unknown
NCT00437359 2012-03-30
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
Japan Breast Cancer Research Network
Phase 2 Terminated